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By using immunohistochemistry we investigated the expression of EphA2 and EphrinA-1 in 217 early squamous 
cell cervical carcinomas and examine their prognostic relevance. For EphA2 expression, 21 tumors (10%) showed 
negative, 108 (50%) weak positive, 69 (32%) moderate positive and 19 (9%) strong positive, whereas for 
EphrinA-1 expression, 33 tumors (15%) showed negative, 91 (42%) weak positive, 67 (31%) moderate positive and 
26 (12%) strong positive. In univariate analysis high expression (strong staining) of EphrinA-1 was associated 
with poor disease-free (P = 0.033) and disease-specific (P = 0.039) survival. However, in the multivariate analyses 
neither EphrinA-1 nor EphA2 was significantly associated to survival. The increased levels of EphA2 and 
EphrinA-1 in a relative high number of early stage squamous cell carcinomas suggested that these two proteins 
may play an important role in the development of a subset of early cervical cancers. However, EphA2 and 
EphrinA-1 were not independently associated with clinical outcome. 
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Introduction 
Worldwide, cervical carcinoma is the second 
most frequent malignancy among women and the 
death rate is 8 per 100,000 [1]. Nearly half of patients 
present with stage I disease and about one third of 
patients treated with surgery received adjuvant 
treatment [2]. This adjuvant treatment is accompanied 
by considerable morbidity [3]. Therefore, it is 
important to make individualized treatment 
procedures in order to reduce negative side effects for 
patients with a good prognosis. Tumor diameter, 
pelvic lymph node metastasis, vascular invasion, deep 
stromal invasion and close resection margins are most 
often used to target adjuvant treatment to those 
patients with highest risk of relapse [4-7]. New 
molecular markers that improve the prediction of 
clinical outcome could be of considerable value to 
design individualized treatment procedures. 
Receptor tyrosine kinases have important roles in 
the development and progression of human tumors 
[8]. Eph receptors represent the largest known family 
of receptors tyrosine kinases and are broadly divided 
into subclasses, EphA and EphB. The EphA receptors 
(A1-A9) bind to EphrinA ligands, a group of glycosyl 
phosphatidylinositol-linked membrane proteins and 
EphB receptors (B1-B6) interact with EphrinB ligands 
[9]. The normal function of EphA2 is not fully 
understood, but it is thought to function in the 
regulation of cell growth, angiogenesis, survival and 
migration [9-11]. EphA2 is overexpressed in a variety 
of human cancers, including breast [12], prostate [13, 
14], oesophagus [15], renal [16], lung [17], pancreas 
[18] and ovarian [19, 20]. Furthermore, increase 
expression of both EphA2 and EphrinA-1 have been 
observed in vulvar carcinomas [21], cervical 
carcinomas [22], bladder carcinomas [23], oesophageal 
carcinomas [24], gastric carcinomas [25] and ovarian 
carcinomas [26]. In various human cancers poor 
outcome for the patients has been associated with 
increase expression of EphA2 and EphrinA-1 [16, 17, 
19, 24, 26]. In our previous study of cervical 
carcinomas FIGO stage I-IV we found that increase 
expression of EphA2 and EphrinA-1 was significantly 
associated with shorter overall survival in multivariate 
analysis [22]. The prognostic significance of EphA2 
and EphrinA-1 expression in early stage cervical 
carcinoma has to our knowledge not been examined. 
The aims of our study were to investigate the Int. J. Med. Sci. 2008, 5 
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expression of EphA2 and EphrinA-1 in a series of 217 
early squamous cell cervical carcinomas and to 
identify predictive markers of the clinical outcome for 
these patients. 
Materials and methods 
Patient materials 
A retrospective study of 217 patients with clinical 
squamous cervical carcinomas FIGO stage IB, treated 
by radical hysterectomy and bilateral pelvic 
lymphadenectomy at The Norwegian Radium 
Hospital in the period January 1987 to December 1993, 
was performed. The median age at diagnosis was 39 
years, ranging from 34 to 51 years. All patients were 
examined under general anesthesia and tumor 
diameter was assessed by inspection and palpation. 
Postoperatively, adjuvant treatment was given in case 
of large tumor diameter, lymph node metastasis, or 
invasion into the parametria. A median of 26 lymph 
nodes were removed. Radiotherapy was given to 32 
patients, radiation and chemotherapy to 12, and 
another 31 received chemotherapy only. All patients 
were followed until death or July 2001. Forty-four 
(20.3%) patients suffered a relapse and 37 (17.1%) died 
of cervical cancer. Median follow-up for patients 
without relapse was 128 months (range from 112 to 146 
months); for patients still alive, median follow-up was 
129 months (range from 114 to 147).  
Histological specimens were reevaluated blindly 
by an experienced pathologist (A. K. L.) for 
histopathological diagnosis according to the World 
Health Organization [27]. Table 1 provides a detailed 
description of the tumor characteristics. As controls, 
we used samples of 10 normal cervices from patients 
who underwent amputation of the cervix for prolapse 
(age range, 31-49 years, median age 43 years). The 
Regional Committee for Medical Research Ethics 
South of Norway (S-06381a), The Social- and Health 
Directorate (06/4509 and 06/4417) and The Data 
Inspectorate (06/01467-3) approved the study. 
Table 1 Ephrin A-1 and EphA2 immunostaining in relation to clinicopathological variables. 
Variables Total  EphA2*  Ephrin  A-1*   
 n  Low  High  (%)  p
‡ Low  High  (%)  p
‡ 
Tumor size (cm)       0.812      0.442 
 < 2  97  88  9 (9)    85  12 (12)   
 2.0 – 3.9  86  78  8 (9)    78  8 (9)   
 ≥ 4  34  32  2 (6)   28  6 (18)  
Depth of invasion (mm)       0.236     0.005 
 ≤ 10  122  113  9 (7)    111  11 (9)   
 11-15  48  45  3 (6)   45  3 (6)  
 > 15  47  40  7 (15)    35  12 (25)   
Vascular invasion       0.716     0.669 
 Absent  117  106  11 (9)    104  13 (11)   
 Present  100  92  8 (8)   87  13 (13)  
Parametrial invasion       0.011     <0.001  
 Absent  202  187  15 (7)    183  19 (9)   
 Present  15  11  4 (27)    8  7 (47)   
Lymph node metastasis       0.680      0.298 
 Absent  175  159  16 (9)    156  19 (11)   
 Present  42  39  3 (7)    35  7 (17)   
Numbers in parentheses are percentages. 
*Low: Negative/weak/moderate staining; High: Strong staining. 
‡Pearson chi-square. 
Immunostaining method 
Sections were immunostained using the Dako 
EnVisionTM + System, Peroxidase (DAB) (K4011, Dako 
Corporation, CA, U. S.A.) and Dakoautostainer. After 
microwaving in 10 mM citrate buffer pH 6.0 to unmask 
the epitopes the sections were treated with 0.03% 
hydrogen peroxide (H2O2) for 5 minutes to block 
endogenous peroxidase. Polyclonal rabbit antibodies 
EphA2 (sc-924, 1:400, 0.5μg IgG/ml) and EphrinA-1 
(sc-911, 1:300, 0.7 μg IgG/ml) both from Santa Cruz 
Biotechnology Inc., CA, U.S.A.  were applied on the 
sections for 30 minutes at room temperature followed 
by incubation with peroxidase labeled polymer 
conjugated to goat anti-rabbit for 30 minutes. The 
peroxidase reaction was developed using 
3`3-diaminobenzidine tetrahydrochloride (DAB) as 
chromogen. Human cervical carcinomas that had been 
shown to express EphA2 and EphrinA-1 have been 
included in all series as positive controls. Negative 
controls included substitution of the polyclonal 
antibody with normal rabbit IgG of the same 
concentration as the polyclonal antibody. All controls 
gave satisfactory results. The specificity of anti-EphA2 
and anti-EphrinA-1 has been tested previously [26]. 
Cytoplasmic staining was considered positive. Four Int. J. Med. Sci. 2008, 5 
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semiquantitative classes were used to describe the 
intensity of staining; no staining, weak staining, 
moderate staining and strong staining. Since tumor 
cells stained uniformly across the samples we did not 
considered the fraction of tumor cells with positive 
staining. Sections were scored by two independent 
observers (R. H. and Z. S.) without knowledge of 
clinical data. Conflicting results were reviewed until 
final agreement was achieved. Based on our previous 
published study of cervical carcinomas FIGO stage 
I-IV two different cutoffs were used [22]. EphA2 and 
EphrinA-1 expression were defined as high when 
strong staining was seen in the tumor cells or, 
alternatively, when strong/moderate staining was 
identified.  
Statistical analyses 
Pearson chi-square test with the Yates continuity 
correction for 2 x 2 tables or Fisher`s Exact test were 
used to test the association between the expressed 
proteins and between protein expression and 
clinicopathological parameters. Using the method 
described by Kaplan and Meier, disease-free and 
disease-specific survival curves were obtained from 
date of diagnosis to relapse or death, respectively, or to 
July 17, 2001. The log rank test with a test for trend in 
case of ordered variables was used for univariate and a 
Cox proportional hazards regression model was used 
for multivariate analysis of survival. In multivariate 
analysis, a backward stepwise regression with a P < 0.1 
in the univariate analysis as the inclusion criterion was 
used. The hazard proportionality was verified by 
computing the log minus log against time. All 
calculations were performed using the SPSS 15.0 
statistical software package (SPSS, Chicago, IL). 
Statistical significance was considered as P < 0.05. 
Results 
In normal squamous epithelium weak 
cytoplasmic staining for EphA2 and EphrinA-1 was 
present in 4/10 (40%) and 6/10 (60%) of the cases, 
respectively. EphA2 and EphrinA-1 staining were seen 
in basal, parabasal and middle layers. For EphA2 
cytoplasmic expression was observed in 196/217 (90%) 
of the cervical cancers, whereas, for EphrinA-1 
cytoplasmic expression was seen in 184/217 (85 %) of 
the cases (Table 2, Figure 1).  
Table 2 Immunostaining results for EphA2 and Ephrin A-1. 
Staining intensity  Number of cases 
  EphA2 (%)  Ephrin A-1 (%) 
Negative  21 (10)  33 (15) 
Weak  108 (50)  91 (42) 
Moderate  69 (32)  67 (31) 
Strong  19 (9)  26 (12) 
 
 
 
Figure 1. Immunohistochemical analysis for EphA2 (A-D) and 
EphrinA-1 (E-H) showing cases with no staining (A, E), weak 
staining (B, F), moderate staining (C, G) and strong staining (D, 
H). 
 
In previous reports [28, 29] protein expression of 
p27, p21, p16, cyclin A, cyclin E and cyclin D3 were 
studied with immunohistochemistry in the same 
patient populations. We therefore make a comparison 
between these proteins and EphA2 and EphrinA-1. 
There was a clear correlation between expression of 
EphA2 and EphrinA-1 (P < 0.0001). No other 
significant relationship concerning protein levels was 
found (Table 3).  
High EphA2 expression (strong staining) was 
significantly correlated to the present of parametrial 
invasion (P = 0.011). There was a clear correlation 
between high EphrinA-1 expression (strong staining) 
and deep invasion (P = 0.005) and presence of 
parametrial invasion (P < 0.001) (Table 1). 
Furthermore, there was a significant association 
between high EphrinA-1 and large tumor size (P = 
0.043) when grouping the staining pattern 
moderate/strong staining as high.  
In the univariate analysis high expression of 
EphrinA-1 (strong staining) was associated with poor 
disease-free (P = 0.033) (Figure 2) and disease-specific 
(P = 0.039) survival (Figure 3, Table 4). No significant Int. J. Med. Sci. 2008, 5 
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correlation was obtained when using strong/moderate 
staining as cutoff for EphrinA-1 or strong and 
strong/moderate staining as cutoff for EphA2 
expression. In the multivariate analyses EphrinA-1 
was not an independent prognostic factor for 
disease-free (P = 0.139) and disease-specific (P = 0.222) 
survival. 
 
Table 3. Correlations. 
Variables EphrinA-1 EphA2  p27
† p21
† p16
† Cyclin  A
† Cyclin  E
† Cyclin  D3
†  
EphrinA-1 1 <0.0001
* 0.883  0.581  0.449  0.160  0.943  0.695 
EphA2   1  0.497  0.825  0.152  0.883  0.944  0.771 
*Correlation is significant at 0.01 level. 
†Anti-p27 (Transduction Laboratories, Lexington, USA), anti-p21 (Oncogene Science, MA, USA), anti-p16 (Neomarkers, CA, USA), anti-cyclin 
A and anti-cyclin E (both from Novocastra Laboratories, Newcastle, UK) and anti-cyclin D3 (Dako, Glostrup, Denmark). Protein levels were 
defined as high when ≥5% of tumor cells were positive for p21, cyclin E and cyclin D3 and ≥50% of tumor cells were positive for p27, p16 and 
cyclin A [28, 29]. 
 
 
Table 4 5-years disease-free and disease-specific survival. 
Variables 
 
Total 
 
Relapses 
N=44 
DFS* 
(%) 
P 
 
Deaths 
N=37 
DSS
† 
(%) 
P 
 
EphA2       0.547      0.748 
 Low 
(negative/weak/moderate) 
198 
 
39 
 
81 
 
 
 
33 
 
85  
 
 
  High  (strong)  19  5 84   4 89   
EphrinA-1       0.033      0.039 
 Low 
(negative/weak/moderate) 
191  35 83   29 87   
  High  (strong)  26  9 73   8 77   
*Disease-free survival.  
†Disease-specific survival. 
 
 
 
 
 
 
 
Figure 2. Disease-free survival in relation to EphrinA-1 
expression. 
 
 
Figure 3. Disease-specific survival in relation to EphrinA-1 
expression. 
 
Discussion 
In the present work, weak immunostaining for 
EphA2 and EphrinA-1 was present in 40% and 60% of 
normal squamous epithelium, respectively. The 
positive overall staining (weak/moderate/strong) of 
EphA2 and EphrinA-1 was observed in 90% and 85% Int. J. Med. Sci. 2008, 5 
 
125
of squamous cell cervical carcinomas FIGO stage IB, 
respectively. This is in line with our previous study 
identifying EphA2 and EphrinA-1 in 88% and 92% of 
squamous cell cervical carcinomas FIGO stage I-IV, 
respectively [22]. Furthermore, high expression 
(moderate/strong staining) for EphA2 and EphrinA-1 
was found in 41% and 43% of the cases, respectively. 
Previously, a wide range of EphA2 overexpression 
(34-87%) [15, 17, 19, 22, 24-26] and EphrinA-1 
overexpression (41-61%) [22, 24, 26] has been reported 
in many other human cancer types FIGO stage I-IV, 
including squamous cell cervical carcinomas were 43% 
and 46% of the cases overexpressed EphA2 and 
EphrinA-1, respectively [22]. The increased levels of 
EphA2 and EphrinA-1 in a relative high number of 
early stage squamous cell carcinomas suggested that 
these two proteins may be important factors in the 
development of a subset of early cervical cancers. This 
is in agreement with the study of Zheng and 
coworkers [14] where EphA2 protein was suggested to 
play an important role in the early stage of prostate 
carcinogenesis. 
Our findings that EphrinA-1 overexpression 
tended to be associated with large tumor size and deep 
invasion are consistent with a recent report by Holm et 
al. [21] in vulvar carcinoma. However, in oesophagus 
cancer [24] and gastric cancer [25] EphrinA-1 
expression did not correlate with tumor size. 
Increased expression of EphA2 was not of 
prognostic significance, whereas overexpression of 
EphrinA-1 (strong staining) was associated with poor 
survival in squamous cell cervical carcinomas FIGO 
stage IB in univariate analysis. However, EphrinA-1 
overexpression was not significantly associated with 
reduced survival when multivariate analysis was 
applied. Contrary, in our previous study of squamous 
cell cervical carcinomas FIGO stage I-IV we found that 
increased expression of EphA2 and EphrinA-1 was 
significantly associated with shorter overall survival in 
multivariate analysis [22]. This discrepancy could not 
be explained by use of different conditions, because in 
these two studies primary antibodies, detection 
system, pretreatment and other technical aspects as 
well as evaluation and cutoffs of 
immunohistochemical results were exactly the same. 
Therefore, our results may indicate that EphA2 and 
EphrinA-1 could be used as an independent prognostic 
factor in squamous cell cervical carcinomas FIGO stage 
I-IV [22], but not when only evaluating early 
squamous cell cervical carcinomas. In other human 
cancers FIGO stage I-IV, high EphA2 [15] and 
EphrinA-1 [21, 24, 30] expressions have been 
correlated with short survival in univariate analysis, 
but not in multivariate analysis. Furthermore, a high 
EphA2 level has been correlated with poor survival in 
univariate analysis as well as in multivariate analysis 
in patients with ovarian carcinomas FIGO stage I-IV 
[19, 26] and oesophagus carcinomas FIGO stage I-IV 
[24]. In contrast, neither EphrinA-1 nor EphA2 was 
associated with survival in patients with carcinomas 
FIGO stage I-IV of ovarian [26] and vulvar [21], 
respectively. Taken together, these studies showed 
that the prognostic significance of EphA2 and 
EphrinA-1 in different human cancers is conflicting 
and no clear picture can be drawn. 
Previously, EphA2 and EphrinA-1 have been 
found to be regulated by p53, p63 and p73 in non-small 
cell lung carcinoma cell line and breast 
adenocarcinoma cell line [31]. In contrast, there was no 
correlation between EphA2 or EphrinA-1 and p53 in 
vulvar cancer [21]. However, EphA2 overexpression 
has been found to be associated with high cyclin A 
level, whereas, increase expression of EphrinA-1 
correlated with high cyclin A and p21 levels in vulvar 
cancer [21]. We did not identify any correlation 
between EphA2 or EphrinA-1 and the cell cycle 
proteins p21, p27, p16, cyclin A, cyclin E and cyclin D3 
in early squamous cell cervical carcinomas. These 
studies may indicate that the mechanisms of 
expression EphA2 and EphrinA-1 are different in 
various types of cancers. 
In conclusion, the increased levels of EphA2 and 
EphrinA-1 in a relative high number of early stage 
squamous cell carcinomas suggested that these two 
proteins may play an important role in the 
development of a subset of early cervical cancers. 
However, EphA2 and EphrinA-1 were not 
independently associated with clinical outcome. 
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